Latest Breaking News On - Epithelial ovarian - Page 1 : comparemela.com

SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and PT Etana Biotechnologies Indonesia ("Etana"), today jointly announced that the Indonesian Food and Drugs Authority (BPOM) has approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug, for five indications including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer(NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer(CC). Etana will commercialize Bevagen in Indonesia under the current licensing agreement with Innovent. Bevagen will potentially

United statesHong kongInnovent biologicsBevagen bevacizumab biosimilarAdimab incyteNathan tirtanaMichael yuEli lillyIndonesian ulema councilNational medical product administrationDrugs authorityMd anderson cancer centerInnovent or companyIncyte corporationInnovent biologics incBiotechnologies indonesia